Propranolol Dosing for Sinus Tachycardia at 27 Weeks Gestation
For a pregnant patient at 27 weeks with sinus tachycardia, start oral propranolol at 10-20 mg three times daily (30-60 mg/day total), with careful titration up to a maximum of 160 mg/day in divided doses if needed for symptom control, while monitoring for fetal bradycardia, hypoglycemia, and maternal hypotension.
Rationale and Evidence-Based Approach
Initial Assessment Required
Before initiating propranolol, you must determine:
- Hemodynamic stability – Is the patient symptomatic with dizziness, chest pain, or shortness of breath?
- Underlying cause – Rule out hyperthyroidism, anemia, infection, or structural heart disease
- Baseline fetal monitoring – Document fetal heart rate before treatment
Dosing Strategy
The ESC guidelines 1 recommend oral metoprolol or propranolol for long-term management of supraventricular tachycardia in pregnancy (Class I, Level C recommendation), though specific dosing is deferred to general arrhythmia guidelines. The Canadian guidelines 2 similarly support beta-blocker use but don't specify exact doses for sinus tachycardia.
Start low and titrate gradually:
- Initial dose: 10-20 mg orally three times daily (30-60 mg/day total)
- Titration: Increase by 10-20 mg/day every 3-7 days based on response
- Target dose: 80-160 mg/day in divided doses (typically sufficient for rate control)
- Maximum dose: Do not exceed 160 mg/day in pregnancy to minimize fetal risks
Critical Safety Considerations
The FDA labeling 3 classifies propranolol as Pregnancy Category C with important warnings:
Fetal/Neonatal Risks:
- Intrauterine growth retardation
- Small placentas
- Bradycardia at birth
- Hypoglycemia
- Respiratory depression
Essential monitoring:
- Neonatal monitoring facilities must be available at delivery
- Serial fetal growth ultrasounds every 3-4 weeks
- Fetal heart rate monitoring at each prenatal visit
- Consider reducing dose or discontinuing 24-48 hours before planned delivery if possible
Pharmacokinetic Considerations
Research demonstrates that propranolol pharmacokinetics are not significantly altered during pregnancy 4, meaning standard dosing principles apply. However, neonatal blood concentrations reach approximately 20% of maternal levels 5, which is higher than animal studies predicted—reinforcing the need for careful fetal monitoring.
Alternative Approach for Refractory Cases
If sinus tachycardia persists despite propranolol 160 mg/day:
- Add digoxin for additional rate control (ESC Class I recommendation) 1
- Consider metoprolol as an alternative beta-blocker (better studied in pregnancy than atenolol, which is contraindicated) 1
- Avoid atenolol completely – ESC gives this a Class III (harm) recommendation in pregnancy 1
Practical Clinical Pearls
Timing of administration: Divide doses three times daily rather than twice daily to minimize peak maternal concentrations and reduce fetal exposure spikes.
When to avoid propranolol:
- First trimester if possible (though not absolutely contraindicated)
- Asthma or significant reactive airway disease
- Heart block or severe bradycardia
- Decompensated heart failure
Postpartum management: Propranolol is excreted in breast milk 3. If continuing therapy postpartum, monitor the infant for bradycardia, hypoglycemia, and respiratory issues. Consider switching to a more selective beta-blocker if breastfeeding is planned long-term.
Documentation Requirements
Document clearly in the medical record:
- Indication for treatment (symptomatic sinus tachycardia)
- Discussion of fetal risks versus maternal benefits
- Plan for neonatal monitoring at delivery
- Arrangements for pediatric/neonatal team availability at birth
The key principle: Use the lowest effective dose, divide it throughout the day, monitor both mother and fetus closely, and ensure neonatal resuscitation capabilities are immediately available at delivery.